spacer
The Healthcare Sales & Marketing Network celebrates 28 years serving the medical sales & marketing community.Connecting Medical Sales Reps with MedTech/BioPharma Recruiters and Independent Reps with and New Product LinesConnecting Medical Sales Reps with MedTech/BioPharma Recruiters and Independent Reps with and New Product Lines

Searching News Database:  rilonacept 

 HSMN NewsFeed - 27 Apr 2016
Novartis Receives Three FDA Breakthrough Therapy Designations for IlaristTo Treat Rare Types of Periodic Fever Syndromes
Biopharmaceuticals FDA
 HSMN NewsFeed - 10 May 2013
Novartis drug Ilaris(R) approved by FDA to treat active systemic juvenile idiopathic arthritis, a serious form of childhood arthritis
Biopharmaceuticals. FDA
 HSMN NewsFeed - 6 Dec 2012
EYLEA(R) (aflibercept) Submitted for EU Marketing Authorization for the Treatment of Macular Edema Following Central Retinal Vein Occlusion
Biopharmaceuticals Ophthalmology Regulatory
 HSMN NewsFeed - 27 Nov 2012
EYLEA(R) (aflibercept) Injection Approved for the Treatment of Wet Age-Related Macular Degeneration in Europe
Biopharmaceuticals Ophthalmology Regulatory
 HSMN NewsFeed - 3 Jan 2012
Regeneron Announces Settlement of Patent Litigation with Genentech for U.S. Ophthalmic Sales of EYLEA(TM) (aflibercept) Injection
Biopharmaceuticals Ophthalmology Licensing
 HSMN NewsFeed - 6 Sep 2011
Regeneron Announces Appointment of Joseph J. LaRosa as Senior Vice President, General Counsel and Secretary
Biopharmaceuticals Personnel
 HSMN NewsFeed - 6 Jun 2011
ZALTRAP (aflibercept) Significantly Improved Survival in Previously Treated Metastatic Colorectal Cancer Patients
Biopharmaceuticals Oncology
 HSMN NewsFeed - 18 Apr 2011
FDA Grants Priority Review for VEGF Trap-Eye for the Treatment of Wet Age-Related Macular Degeneration
Biopharmaceuticals Ophthalmology
 HSMN NewsFeed - 8 Apr 2011
Regeneron and Bayer Announce Start of Phase 3 Clinical Program in Diabetic Macular Edema
Biopharmaceuticals Ophthalmology
 HSMN NewsFeed - 10 Mar 2011
Sanofi-aventis and Regeneron Report Top-line Results from Phase III Study with aflibercept (VEGF Trap) in Second-Line Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 20 Dec 2010
Regeneron and Bayer Report Positive Results for VEGF Trap-Eye in Phase 3 Study in Central Retinal Vein Occlusion (CRVO) and in Phase 2 Study in Diabetic Macular Edema (DME)
Biopharmaceuticals Ophthalmology
 HSMN NewsFeed - 15 Nov 2010
Christine A. Poon Elected to Regeneron Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 24 Jul 2009
Regeneron Receives European Medicines Agency Positive Opinion for Marketing Authorization of Rilonacept for the Treatment of Cryopyrin-Associated Periodic Syndromes (CAPS)
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 30 Apr 2009
Bayer and Regeneron Extend Development Program for VEGF Trap-Eye to Include Central Retinal Vein Occlusion
Biopharmaceuticals Ophthalmology
 HSMN NewsFeed - 19 Aug 2008
Regeneron and Bayer HealthCare Announce VEGF Trap-Eye Achieved Durable Improvement in Vision over 52 Weeks in a Phase 2 Study in Patients with Age-Related Macular Degeneration
Biopharmaceuticals Opthalmology
 HSMN NewsFeed - 8 May 2008
Bayer and Regeneron Dose First Patient in Second Phase 3 Study for VEGF Trap-Eye in Wet Age-Related Macular Degeneration
Biopharmaceuticals Ophthalmology
 HSMN NewsFeed - 28 Apr 2008
Regeneron and Bayer HealthCare Announce Encouraging 32-Week Follow-Up Results from a Phase 2 Study of VEGF Trap-Eye in Age-Related Macular Degeneration
Biopharmaceuticals Ophthalmology
 HSMN NewsFeed - 25 Mar 2008
ARCALYST(TM) (rilonacept), First and Only FDA-approved Treatment for Cryopyrin-Associated Periodic Syndromes (CAPS), Now Available in the United States
Biopharmaceuticals
 HSMN NewsFeed - 27 Feb 2008
FDA Approves Regeneron's ARCALYST(TM) (rilonacept) for Treatment of Cryopyrin-Associated Periodic Syndromes (CAPS)
Biopharmaceuticals FDA
 HSMN NewsFeed - 8 Aug 2007
Rilonacept (IL-1 Trap) Granted FDA Priority Review for the Treatment of CAPS
Biopharmaceuticals
 HSMN NewsFeed - 8 Jun 2007
Regeneron Submits Biologics License Application to U.S. FDA for IL-1 Trap (Rilonacept) for Treatment of CAPS
Biopharmaceuticals
Return to NewsFeed  
FindReps - screen and connect with rep candidates anonymously, in real time.

FindReps: Screen and connect with Medical Sales Rep candidates (Direct Reps and Independents) – anonymously, in real time.


RepJobs - Job Opportunities for Direct Sales Reps and New Product Lines for Independents!

RepJobs: Job Opportunities for Direct Sales Reps and New Product Lines for Independents!